期刊文献+

奥沙利铂、5-氟尿嘧啶、甲酰亚叶酸钙联合化疗治疗晚期结直肠癌的临床疗效与耐受性的随机对照观察 被引量:2

The Observation on Clinical Efficacy and Tolerability of the Method Containing Oxaliplatin, 5-fluorouracil and Formyl Calcium Folinate in the Treatment of Advanced Colorectal Cancer
下载PDF
导出
摘要 目的观察奥沙利铂、5-氟尿嘧啶、亚叶酸钙联合方案治疗晚期结直肠癌的临床疗效与耐受性,优化晚期直肠癌的化疗方案。方法将符合入组标准的80例晚期结直肠癌随机分为观察组40例和对照组40例,对照组给予顺铂、5-氟尿嘧啶、甲酰亚叶酸钙联合化疗治疗,观察组给予奥沙利铂、5-氟尿嘧啶、甲酰亚叶酸钙联合化疗治疗,28d为1个周期,治疗4个周期,治疗前后进行实验室辅助检查,评价两组临床近期疗效与远期疗效,记录实验过程中的不良反应。结果①观察组的总有效率为52.5%,对照组的总有效率为30%,观察组的总有效率明显高于对照组,差异具有统计学意义,χ2=8.182,P<0.05;观察组的1年生存率为87.5%,明显高于对照组,χ2=6.667,P<0.05;观察组的3年生存率为62.5%,明显高于对照组,χ2=5.000,P<0.05;②两组患者治疗过程出现的不良反应有贫血、白细胞减少、血小板减少、恶心呕吐、腹泻、口腔炎、脱发、肝损害,观察组出现贫血、白细胞减少、腹泻的几率明显低于对照组,差异具有统计学意义,均P<0.05。结论奥沙利铂、5-氟尿嘧啶、亚叶酸钙联合方案近期疗效、远期疗效及安全性均明显优于顺铂、5-氟尿嘧啶、亚叶酸钙,明显改善患者生活质量,值得临床广泛推广运用。 Objective To observe the clinical efficacy and tolerability of the method containing Oxaliplatin,5-fluorouracil and formyl calcium folinate in the treatment of advanced colorectal cancer,to optimize the advanced rectal cancer chemotherapy.Methods 80 advanced colorectal cancer patients met inclusion criteria were randomly divided into 40 cases of the control group and 40 cases of the observation group,the control group were given cisplatin,5-fluorouracil,formyl calcium folinate,the observation group were treated with oxaliplatin,5-fluorouracil,formyl calcium folinate,28d for a cycle,two group were treated for four cycles,all patients were given laboratory assistant examination before and after treatment,clinical efficacy,long-term efficacy and the adverse reactions were compared.Results ①The total effective rate of the observation group was 52.5%,the control group was 30%,the observation group was significantly higher than the control group,χ2=8.182,P0.05;the 1-year survival rate of the observation group was 87.5%,the observation group was significantly higher than the control group,χ2=6.667,P 0.05;3-year survival rate of the observation group was 62.5%,the observation group was significantly higher than the control group,χ2=5.000,P 0.05;②the adverse reactions of the two groups during the treatment were anemia,leukopenia,thrombocytopenia,nausea,vomiting,diarrhea,stomatitis,alopecia,liver damage,the anemia,neutropenia,diarrhea of the observation group was significantly lower than the control group,the difference were statistically significant,P 0.05.Conclusion The method containing oxaliplatin,5-fluorouracil and leucovor have better short-term effect,long-term efficacy and safety,and were significantly superior than the method containing cisplatin and 5-fluorouracil,leucovorin,and significantly improve patients' quality of life,was worthy to use.
作者 邢怡
出处 《中国医药指南》 2013年第2期38-39,共2页 Guide of China Medicine
关键词 奥沙利铂 联合化疗 晚期结直肠癌 Oxaliplatin Combination chemotherapy Advanced colorectal cancer
  • 相关文献

参考文献7

二级参考文献44

共引文献48

同被引文献35

  • 1Jemal A, Tiwari RC, Murray T,et al. Cancer statistics, 200d-[J]. CA Cancer J Clin, 2004,54( 1 ) :8-29.
  • 2Verschraegen CF, Pazdur R. Medical management of colorectal carcinomas[ J]. Tumori, 1994,80( 1 ) : 1-11.
  • 3陈卫彬,诸葛晋.FOLFOX方案在中晚期大肠癌治疗中的安全性观察[J].当代医药,2012,18(3):92-93.
  • 4Raymond E, Faivre S, Woynarowski JM,et al. Oxaliplatin : mech- anism of action and antineoplastic activity [ J ]. Semin Oncol, 1998,25(2 Suppl 5) :4-12.
  • 5Bleiberg H. Oxaliplatin (L-OHP): a new reality in colorectal cancer[J]. Br J Cancer, 1998,77(4) :1-3.
  • 6Chu E, Shi N, Wei W, et al. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer [ J ]. Oncology, 2009,77 ( 3-4 ) :244-253.
  • 7Waddell T, Gollins S, Soe W, et al. Phase II study of short- course capecitabine plus oxaliplatin (XELOX) followed by main- tenance capecitabine in advanced colorectal cancer: XelQuali study[ J ]. Cancer Chemother Pharmacol, 2011,67 ( 5 ) : 1111- 1117.
  • 8Lubner SJ, Loconte NK, Holen KD, et al. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer[J]. Clin Colorectal Cancer, 2010,9(3) :157-161.
  • 9Cassidy J, Tabernero J, Twelves C, et al. XELOX ( capecitabine plus oxaliplatin) : active first-line therapy for patients with meta- static colorectal cancer [J]. J Clin Oncol, 2004,22( ll ) :2084- 2091.
  • 10Ramani VS, Sun Myint A, Montazeri A, et al. Preoperative che- moradiotherapy for rectal cancer: a comparison between intrave- nous 5-fluorouraeil and oral capeeitabine [ J ]. Colorectal Dis, 2010,12 Suppl 2:37-46.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部